P

Phil

Digital platform enabling expedited prescription access

Head of Product - Market Expansion

Full-Time
$190k - $210k/yr
Expert
MBA
Remote in USA+1 moreMore locations: San Francisco, CA, USA
RemoteFully remote, limited to the listed U.S. states.

About the job

Requirements
  • 10+ years of product management experience, including at least 3 years converting organizational business strategy into clear product requirements and outcomes.
  • Experience in healthcare, ideally in pharmacy operations, electronic health record systems, payer and plan integrations, or related areas.
  • Ability to define and drive product strategy in complex, regulated, and mission-critical domains.
  • Fluency with data and metrics, including experience setting and managing product key performance indicators and operational service-level agreements.
  • Deep understanding of technical systems and ability to collaborate effectively with engineering teams.
  • Ability to influence senior leadership, including C-suite leaders, on product strategy and prioritization to optimize business outcomes.
  • Ability to thrive under pressure, act decisively, launch solutions rapidly, prioritize ruthlessly, and deliver results as a highly independent individual contributor.
  • Proven use of artificial intelligence in actual product solutions, including continuous learning systems and development efficiency.
  • Education or relevant experience in healthcare or pharmacy.
Responsibilities
  • Own and evolve the strategic roadmap for market and therapeutic-area expansions, including specialty pharmaceuticals, controlled substances, and biologics, while aligning technical capabilities with business priorities.
  • Benchmark industry best practices and build a plan to achieve best-in-class service offerings based on strategic direction and priorities.
  • Drive improvements in PHIL solutions through optimized processing and deliberate use of third-party integrations versus internal capabilities.
  • Develop and champion new platform capabilities supporting expanded therapeutic categories and patient therapy management.
  • Set long-term success metrics and operational key performance indicators, ensuring the product roadmap aligns with measurable outcomes.
  • Lead cross-functional partnerships with senior stakeholders across Product, Engineering, Operations, and Commercial teams to define priorities and deliver value.
  • Lead discovery efforts and user research to identify opportunities, prioritize work, maintain organizational focus, and drive specific outcomes.
  • Mentor product team members and elevate overall product team capability through thought leadership, strategic rigor, and operational depth.
Desired Qualifications
  • Master of Business Administration.

About the company

Phil.us offers PhilRx, a digital health platform that streamlines obtaining prescribed medications for patients and helps providers manage care. It coordinates clinicians, payers, and pharmacies through a national dispense network, real-time HIPAA-compliant data, and workflows for prior authorization and formulary access. It stands out by delivering an integrated medication-access workflow along with consulting services and telemedicine, not just software. Its goal is to improve patient adherence and increase insured prescriptions while earning revenue from platform subscriptions, consulting services, and potential per-prescription economics.

Company Size

201-500

Company Stage

Debt Financing

Total Funding

$158.6M

Headquarters

Scottsdale, Arizona

Founded

2015

Get referred to Phil

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • K2 HealthVentures gave PHIL a $60 million growth facility on January 8, 2026.
  • PHIL launched YUVEZZI in April 2026 and New Day Skin Spray on September 1.
  • PHIL expanded cash dispense capabilities in April 2026 to serve broader DTP volume.

What critics are saying

  • PHIL depends on a few manufacturer deals; losing Tenpoint or Sprout crushes revenue.
  • CVS Specialty, Shields Health Solutions, and Eversana directly attack PHIL's same-day commercialization niche.
  • PBM and state-regulator scrutiny of cash-pay DTP programs destroys PHIL's transaction volume.

What makes Phil unique

  • PHIL Direct 2.0 bundles EMR prescribing, prior authorizations, insurance, telehealth, and delivery.
  • PHIL converts pharma launches into same-day direct-to-patient access with fulfillment and support.
  • Tenpoint, Sprout, and Evolved Health chose PHIL for 2026 commercial programs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

↓ -1%

1 year growth

↑ 1%

2 year growth

↑ 1%
Associated Press
Sep 1st, 2026
PHIL and Evolved Health launch New Day Skin Spray direct-to-patient programme for atopic dermatitis

PHIL, a technology-powered patient access platform, has partnered with Evolved Health to launch the New Day™ Skin Spray Direct-to-Patient programme. The prescription topical emulsion spray treats mild to severe atopic dermatitis and is now available in select US markets, with a broader national rollout planned. The therapy uses peptide technology from Evolved By Nature, developed into a medical device by Evolved Health. It can be used alone or alongside other treatments, with no washout periods or systemic exposure required. Atopic dermatitis affects an estimated 19.8 million adults and 9.2 million children in the United States. Research shows over 40% of diagnosed patients pay more than $1,000 annually in out-of-pocket treatment costs. Patients prescribed the spray pay a $15 copay with no prior authorisation required. The product ships free within three to five days.

Business Wire
Apr 2nd, 2026
Tenpoint Therapeutics partners with PHIL to launch direct-to-patient cash program for YUVEZZI presbyopia therapy

Tenpoint Therapeutics and PHIL Inc. have launched a direct-to-patient cash programme for YUVEZZI, the first FDA-approved dual-agent prescription eye drop for presbyopia treatment. The programme aims to improve access to the therapy through affordable pricing, home delivery and dedicated support. Presbyopia affects nearly 128 million Americans and approximately 2 billion people globally, with many patients going untreated due to high out-of-pocket costs and limited access. The partnership seeks to reduce these barriers and support long-term treatment adherence. YUVEZZI contains carbachol and brimonidine tartrate ophthalmic solution at 2.75%/0.1% concentration. PHIL operates a healthcare technology platform that connects pharmaceutical manufacturers with patients to provide more convenient and affordable medication access.

PharmiWeb
Apr 2nd, 2026
Tenpoint Therapeutics Ltd and PHIL partner to launch YUVEZZI(TM) direct-to-patient cash program to make novel presbyopia therapy more accessible and affordable.

Tenpoint Therapeutics Ltd and PHIL partner to launch YUVEZZI(TM) direct-to-patient cash program to make novel presbyopia therapy more accessible and affordable. SCOTTSDALE, Ariz.-(BUSINESS WIRE)-Tenpoint Therapeutics, a leading ophthalmic manufacturer, and PHIL Inc., an all-in-one digital hub and Direct-to-Patient platform, today announced the launch of a Direct-to-Patient (DTP) cash program for YUVEZZI(TM), the first and only dual-agent prescription eye drop FDA-approved for the treatment of presbyopia. Why Direct-to-Patient Access Matters for Presbyopia Patients Access and adherence remain persistent challenges in ophthalmology, where treatments are often underutilized due to a complex patient journey with high affordability barriers. Presbyopia, an ophthalmic condition that affects nearly 128 million Americans and approximately 2 billion people globally, has traditionally seen patients go untreated due to high out-of-pocket costs and limited therapy access (AOA, 2023). The opportunity to help meaningfully improve access to presbyopia therapy for millions of patients has never been greater. Modernizing the Access Journey for YUVEZZI(TM) Tenpoint and PHIL have partnered to launch an innovative DTP program, delivering YUVEZZI(TM) directly to patients through a seamless access experience with affordable, transparent pricing, home delivery, and dedicated support. This groundbreaking partnership reflects our shared commitment to improving how presbyopia patients receive therapy through reducing access barriers, lowering out-of-pocket costs, and supporting long-term treatment adherence for presbyopia patients. "We are excited to partner with Tenpoint Therapeutics as they launch YUVEZZI(TM)- a meaningful leap forward for presbyopia patients across the country. For the 128 million Americans living with this condition, our direct-to-patient program provides a seamless and accessible path to this innovative therapy. This partnership demonstrates what's possible when patient access is a top priority." - Deepak Thomas, CEO & Founder, PHIL About Tenpoint: Tenpoint Therapeutics Ltd. is an ophthalmic pharmaceutical company focused on the commercialization of YUVEZZI(TM)(carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, the first and only dual-agent eye drop for the treatment of presbyopia, a condition that affects nearly 128 million people in the U.S. and approximately 2 billion people globally.[1,2] By understanding real-world needs and partnering with eye care professionals, Tenpoint is working to bring innovation to the aging eye. For more information, visit tenpointtherapeutics.com. About PHIL Inc.: PHIL is a healthcare technology platform that partners with pharmaceutical manufacturers to empower patients with more convenient and affordable access to their prescribed medications. Through PHIL's digital hub and direct-to-patient platform, PHIL supports access, affordability, and adherence at scale. For more information, visit phil.us. [1] American Optometric Association Health Policy Institute. New Approaches to Presbyopia. 2023. Accessed November 5, 2025. Available at https://www.aoa.org/AOA/Documents/Advocacy/HPI/presbyopia%20brief%20HPI%20Final.pdf. [2] Fricke TR, Tahhan N, Resnikoff S, et al. Global Prevalence of presbyopia and vision impairment from uncorrected presbyopia: systematic review, meta-analysis and modelling. Ophthalmology. 2018;125(10):1492-9. Editor details. * Company: * Businesswire Last Updated: 02-Apr-2026

FinSMEs
Jul 9th, 2025
Phil Receives $60M Growth Capital Facility from K2 HealthVentures

Phil receives $60M growth capital facility from K2 HealthVentures.

Health Technology Insights
Jul 8th, 2025
Phil Secures $60 Million Growth Capital from K2 HealthVentures to Boost AI Integration

Phil, a leading software-driven pharmaceutical commercialization platform, announced a $60 million growth debt financing from K2 HealthVentures, a healthcare and life sciences-focused investment firm.